



# Innovation in Healthcare

from Research to Market  
30, 31 March 2011  
Brussels Flagey

**MEET THE SPEAKERS**

## **TABLE OF CONTENTS**

Margaret ANDERSON, Executive Director, FasterCures.....	5
Thomas BOLS, Vice President Corporate Health Policy and Market Access, Merck Serono.....	6
Angela BRAND, Director, Institute for Public Health Genomics (IPHG).....	7
Tine BRYAN STENSBOEL, Divisional Director for Discovery Pharmacology Research, Lundbeck .....	8
Emmanuel CHANTELOT, Director, European Government Relations and Public Policy, Shire.....	9
Maria da Graça CARVALHO, Member of the European Parliament.....	10
John DALLI, Commissioner for Health and Consumer Policy, European Commission.....	11
Marco d'ANGELANTONIO – CEO, Health Information Management S.A.....	12
Marc DE GARIDEL, President, European Biopharmaceuticals Enterprises (EBE), Chairman and Chief Executive Officer, Ipsen.....	13
Rudy DEKEYSER, Managing director, Technology transfer, Imperial Innovations.....	14
Giulia DEL BRENNA, Head of Unit, Food and Healthcare Industries, Biotechnology, DG Enterprise and Industry, European Commission.....	15
Andras DINNYES, Director, BioTalentum.....	16
Ruxandra DRAGHIA-AKLI, Director, Directorate Health,DG Research and Innovation, European Commission.....	17
Peter DROELL, Head of Unit, Policy Development for Industrial Innovation, DG Enterprise and Industry, European Commission .....	18
Ernő DUDA, President, Hungarian Biotechnology Association, President and Chief Executive Officer, Solvo Biotech.....	19
Anne-Kirstine DYRVIG, Coordinator, Odense University Hospital.....	20
Björn EKSTRÖM, President and Chief Executive Officer, Olink.....	21
Pietro FOLINO GALLO, Director of Medicines Utilisation and Expenditure and HTA, Italian Medicines Agency.....	22
Máire GEOGHEGAN-QUINN, Commissioner for Research, Innovation and Science,	

European Commission.....	23
Bernard GIBIS, Director,	
National Association of Statutory Health Insurance Physicians Germany.....	25
Iain M. GILLESPIE, Head of Science & Technology Policy Division,	
Directorate for Science, Technology and Industry, OECD.....	26.
Audrey GOOSEN, Policy Officer, Knowledge transfer: University-industry relations,	
Innovation Policy Unit, DG Research & Innovation, European Commission.....	27
Frank HEEMSKERK, founder and CEO of	
Research & Innovation Management Services bvba .....	28
Tony HICKSON, Managing Director of Technology Transfer, Imperial Innovations.....	29
Stéphane HOGAN – Head of Coordination Unit, Directorate Health,	
DG Research & Innovation, European Commission.....	30
Philippe JACON, Director General, EDMA.....	31
Panos KANAVOS, Director, Health and Department of Social Policy,	
London School of Economics.....	32
Alastair KENT, Chairman, Chairman, European Platform for Patients' Organizations,	
Science and Industry (EPPOSI).....	33
Nevenka KREGAR VELIKONJA, Director, Educell.....	34
Torbjörn KRONANDER, CEO, Sectra.....	35
Ludovic LACAINE, Director, Health Care Biotechnology Europabio.....	36
Guy J. LEBEAU, Chairman,	
European Medical Technology Industry Association (Eucomed).....	37
Julianna LISZIEWICZ, PhD, President, Chief Executive Officer, Genetic Immunity.....	38
Joël JEAN-MAIRET, Managing Partner, Ysios Capital Partners.....	39
Nathalie MOLL, Secretary General, EuropaBio .....	40
Stefan NARDI-HIEBL, Head of Siemens Healthcare Consulting, Siemens AG,	
Siemens Healthcare Consulting.....	41
Daniel NELKI, Head of Legal and Operations, Wellcome Trust.....	42
Anders OLAUSON, President, European Patients' Forum.....	43

Andrea RAPPAGLIOSI, Co-chair HTA Task Force, European Federation of Pharmaceutical Industries and Associations, Vice President, GlaxoSmithKline.....	44
John R. RIDGE, Director of Reimbursement Services and Health Economics, Roche Tissue Diagnostics.....	45
Andrzej RYŚ, Director in Directorate C – “Public Health and Risk Assessment”, DG "Health and Consumers", European Commission.....	46
Robert-Jan SMITS, General Director, DG Research and Innovation, European Commission.....	47
Christian J. Suojanen, Head of Life Sciences, Valor Management S.A., & Co-Chairman, Tech Transfer Summit Initiative. ....	48
Miklós SZÓCSKA, Minister of State for Health, Hungarian Presidency of the Council of the European Union.....	49
Antonio TAJANI, Vice-President of the European Commission, responsible for Industry and Entrepreneurship.....	50
Cécile THARAUD, CEO, Inserm transfer, Vice-President Association of European Science and Technology Transfer Professionals (ASTP).....	51
Patrick TRICOLI, Scouting & Partnering International, Sanofi Aventis.....	52
Piyush UNALKAT, Principal, Transaction Relationship Management (Technology Transfer), European Investment Fund.....	53
Onno VAN DE STOLPE, CEO, Galapagos Genomics.....	54
Jacques VISEUR, Managing Director, Eurotop Cooperation Partners.....	55
Simon VRHUNEC, Director, University Medical Centre Ljubljana.....	56
Mike WARD, Editor, Scrip Intelligence, Informa Group.....	57
Lilian WIKSTRÖM, CEO, Karolinska institutet Holding AB.....	58
John WILKINSON, Chief Executive, Eucomed.....	59
Jean-Jacques ZAMBROWSKI, Hospital Physician and Professor of Health Economics, Paris Descartes University.....	60
Gerd ZETTLMEISSL, CEO, Intercell.....	61

## Margaret ANDERSON, Executive Director, FasterCures



Margaret Anderson is Executive Director of *FasterCures/The Center for Accelerating Medical Solutions*, defining the organization's strategic priorities and positions on key issues, developing its programmatic portfolio, and managing its operations. Prior to her appointment, she was *FasterCures'* COO for five years. Margaret previously served as deputy director of the Academy for Educational Development (AED) and led programs and studies at the Society for Women's Health Research, the American Public Health Association and the Congressional Office of Technology Assessment.

She currently serves on the boards of the Alliance for a Stronger FDA, the Council for American Medical Innovation, and the Coalition for the Advancement of Medical Research, and has held numerous committee and coalition memberships for federal agencies and professional associations in the biomedical and public health arena.

Margaret holds a bachelor's degree from the University of Maryland and a master's degree in science, technology and public policy from George Washington University's Elliott School of International Affairs.

### **Presentation**

"Finding Big Ideas in Small Spaces – New Patient-Driven Business Models to Accelerate Research"

**Thomas BOLS,  
Vice President Corporate Health Policy and Market Access,  
Merck Serono**



Thomas is Merck Serono's Vice President Corporate Health Policy and Market Access, since 1 September 2009, based in Geneva. Before that he was for six years Director Government Affairs Europe for Amgen International and a member of the Amgen European Leadership Team. Previously, he has been working for management consultancies, industry federations and the EU Institutions.

Since June 2009, he is the Chairman of the healthcare Council of EuropaBio, the European biotechnology industry federation, and a member of its board.

Thomas studied Political Sciences at the University of Amsterdam and holds a postgraduate degree in European Law. A Dutch citizen, he lives in Brussels and Geneva and speaks Dutch, English, German, Spanish and French.

**Angela BRAND,  
Director, Institute for Public Health Genomics (IPHG)**



Prof. Angela Brand, MD PhD MPH is Director of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University, the Netherlands, and Director of the European Centre for Public Health Genomics (ECPHG).

Prof. Brand is Coordinator of the Public Health Genomics European Network (PHGEN), President of the Section Public Health Genomics within the European Public Health Association (EUPHA), Editor-in-Chief of the international journal Public Health Genomics, Executive Director of the Public Health Genomics international network GRaPH-Int, Associated Member of the international consortium Public Population Project in Genomics (P<sup>3</sup>G) on biobanking, Advisory Board Member of Alacris Pharmaceuticals, Advisory Board Member of OncoTrack (IMI), Scientific Consultation Group Member of the European Centre for Disease Prevention and Control (ECDC), and Co-Investigator of PIE (Pharmacogenomics & Innovation in Ethics) within the NIH Pharmacogenetics Research Network (PGRN).

Prof. Brand serves as Expert for various organizations such as the European Agency for Reconstruction, the OECD, WHO, the European Commission, the Netherlands Genomics Initiative (NGI), the German Robert Koch-Institut (RKI), Genome Canada, the European Science Foundation). She is Fellow of the Rockefeller Foundation, USA, and of the 21<sup>st</sup> Century Trust of the Wellcome Trust, UK. She is Pediatrician and Specialist in Public Health Medicine, holds a PhD in pathology (Münster University, Germany) and a Master of Public Health (Johns Hopkins University, USA) and received her habilitation in Public Health Genomics (Bremen University, Germany).

**Presentation**

"Public Health Genomics goes personalized: Setting the scene"

**Tine BRYAN STENSBØL,  
Divisional Director for Discovery Pharmacology Research, Lundbeck**



Dr Tine Bryan Stensbøl is the Divisional Director for Synaptic Transmission Research at Lundbeck.

Tine Bryan Stensbøl graduated from The University of Pharmaceutical Sciences in Copenhagen in 1993, where she continued her PhD studies in Medicinal Chemistry and Molecular Pharmacology within the glutamate field. After a post doc period at the University of Pharmaceutical Sciences, she started at Lundbeck in 2001 as a research scientist. Here she became the project lead of one of Lundbecks discovery projects in depression successfully pushing 4 compounds into development 2 of which are now in phase 2 and 3 clinical trials. Tine now directs a biology-driven focus area at Lundbeck, namely Synaptic transmission Research and is a member of the Drug Discovery Management Team responsible for the outlining as well as implementing of Lundbecks strategic research plan in DK.

Further to this she is the coordinator of a public private partnership under the Innovative Medicines Initiatives (IMI) umbrella called NEWMEDS, focusing on addressing the major need for improved treatments for depression and schizophrenia and involves 23 partners comprising pharmaceutical companies, SMEs and leading academic institutions in Europe.

**Presentation**

"NEWMEDS - a public private partnership under the IMI-JU initiative"

**Emmanuel CHANTELOT,  
Director, European Government Relations and Public Policy, Shire**



As the head of European government relations across all business units at Shire, Mr. Chantelot is responsible for developing Shire's relationships with the European institutions and building strategic partnerships with key stakeholders in Brussels. He helps foster understanding about Shire's business with governments and public policy stakeholders and influencers across Europe.

Mr. Chantelot joined Shire in January 2011, with 18 years of international experience in policy advocacy, strategic communications and business interest representation towards the EU Institutions, global agencies and national governments. He was previously the Executive Director of European Biopharmaceutical Enterprises (EBE), a European trade association of 63 biopharmaceutical companies operating as the biotechnology arm of EFPIA, the European pharmaceutical industry federation. Before joining EBE in June 2006, Mr. Chantelot occupied senior management positions in global and European trade associations for different industry sectors and in an international management consultancy.

Mr. Chantelot graduated with Masters Degrees in molecular biology and biotechnology from the Free University of Brussels and received management education at Northwestern University in Chicago. He is a Belgian national.

**Maria da Graça CARVALHO,  
Member of the European Parliament**



Maria da Graça Carvalho is a Member of the European Parliament in the EPP Group, Member of the Industry Research and Energy Committee, substitute member of the Budgets Committee, substitute member of the Policy challenges and budgetary resources post-2013 Committee, member of the ACP-UE Joint Parliamentary Assembly, and substitute member of the Delegation to the Parliamentary Assembly of the Union for the Mediterranean. She was elected Co-President of the Economic Development, Finance and Trade Committee of ACP-UE Joint Parliamentary Assembly.

She has been Principal Adviser of President Barroso in the areas of Science, Higher Education, Innovation, Research Policy, Energy, Environment and Climate Change from 2006 to 2009.

She is a Full Professor at Instituto Superior Técnico (Technical University of Lisbon) and she has a 30 years research experience in the areas of energy, environment and climate change. In 1983 she obtained her Ph.D. at the Imperial College in London in the area of energy intensive industries.

She has been Minister of Science and Higher Education of the XV Constitutional Government of Portugal and Minister of Science, Innovation and Higher Education of the XVI Constitutional Government.

**Presentation**

"The Future of EU Research and Innovation Programmes"

**John DALLI,  
Commissioner for Health and Consumer Policy, European Commission**



John Dalli served as a Cabinet Minister in the Maltese Government since 1987 having been first elected to the House of Representatives of Malta on behalf of the Nationalist Party in 1987. He has served as Parliamentary Secretary for Industry (1987-1990), Minister of Economic Affairs (1990-92), Minister of Finance (1992-1996, 1998-2003) Minister of Finance and Economic Affairs and Minister of Foreign Affairs and Investment Promotion (2004). Between March 2008 and February 2010, John Dalli served as Minister for Social Policy which includes the Health, housing, employment and industrial relations portfolio.

As a qualified accountant, Dalli has also worked in the private sector in Malta and abroad, both in industry and as an independent consultant.

In February 2010 John Dalli was appointed as European Commissioner responsible for Health and Consumer Policy.

John Dalli was born on 5th October 1948. He is married and has two daughters.

**Marco d'ANGELANTONIO,  
CEO, Health Information Management S.A.**



After 21 years with the Italian Group Olivetti, for which he worked in Belgium, Italy, Spain and the United Kingdom, Marco founded in 1997 HIM, a Brussels-based SME specialised in the fields of telecare and telehealth.

With the new company he has master minded and managed several European projects in the areas of eHealth and eInclusion funded under different EU Programmes (4 and 5FP, eTEN and ICT PSP). His involvement in these projects has allowed him to gain a remarkable knowledge and understanding of the different healthcare systems in the European Union and to establish a strong network of relations with healthcare providers, national and regional health authorities in various countries, and IT companies active in this market.

He has been often invited as a guest speaker to major conferences and seminars. He has proven ability to lead multi-language and multi-cultural teams because of his deep understanding of cultural differences in Europe, and his language skills (he is fluent in Italian, English, French and Spanish).

**Presentation**

“SMEs and European Programmes: opportunity or fatal attraction?”

**Marc DE GARIDEL,  
President, European Biopharmaceuticals Enterprises (EBE),  
Chairman and Chief Executive Officer, Ipsen**



Marc de Garidel is Chairman and Chief Executive Officer of Ipsen Group, a global biopharmaceutical Group.

Prior to this position, Marc de Garidel was a vice-president of Amgen International, responsible for the South Region. His region includes Southern Europe territories, Turkey, Middle-East, Africa, & South America. Prior to that assignment, he was in charge of the Southwest region in 2006 & of the French affiliate between 2000 & 2005. Marc de Garidel built in that period the largest affiliate outside of the US.

He started with Amgen in 1995 as VP Finance Europe & became Corporate Controller of Amgen Inc in 1998.

Marc de Garidel gained his first professional experience with Eli Lilly working in several functions & in different countries such as the US, Germany & France.

Marc de Garidel is a graduate of the Executive MBA at Harvard Business School (AMP), has Master's Degree in International Management & Master's in Civil Engineering.

Besides his current responsibilities, he is President of EBE (European Biopharmaceutical Enterprises) since June 2010 and member of the Board of EFPIA, European Federation of Pharmaceutical Industries and Associations. He has been a founder & president of the French LEEM Biotech Association between 2004 & 2006. Since January 2011, Marc de Garidel is Chairman and Spokesman of the G5, an association of French companies specialized in health and life sciences (bioMérieux, Ipsen, LFB, Pierre Fabre, sanofi-aventis and Servier are companies whose decision-making centres are based in France, are internationally competitive and make research efforts a high priority).

He is also Chairman of the Board of Promothera Bioscience, a cell therapy start-up in Belgium. He is also Member of the Board of TCland Expression & Protein Therapeutics.

Marc de Garidel is also Chevalier de la Légion d'Honneur & is a co-author of a book called « La Société du Médicament » published in 2006."

**Rudy DEKEYSER,**  
**Managing director, Technology transfer, Imperial Innovations**



Rudy Dekeyser is managing director of VIB and head of VIB's technology transfer department. VIB is a life sciences research institution located in Flanders, Belgium with 1.300 researchers from 60 different nationalities. VIB's mission is to conduct frontline research and to translate the research findings into products for the benefit of society. VIB inked almost 800 deals with companies, established 11 start-ups which raised 434 M€ in private and public capital and employ almost 500 people, exploits 12.000 m<sup>2</sup> bio-incubator facilities and is a catalyst in building a regional life sciences cluster. VIB has structural partnerships with the universities of Gent, Leuven, Antwerp and Brussels.

Rudy Dekeyser has been board member at Devgen, CropDesign and Ablynx nv, and is board member at Pronota nv, Actogenix nv, Remynd nv, CardioBiosciences sa, Bio-Incubator Leuven nv, Solucel OY, Biolign nv, Multiplicom nv, EMBLEM (the EMBL tech transfer company) and FlandersBio (the Flemish biotech association). He is also co-founding board member of the Association of European Science and Technology Transfer Professionals (ASTP), chairman of the Valorisation Advisory Board of the Netherlands Genome Initiative (NGI) and member of the scientific advisory board of the LifeSciencesAmsterdam Fund and the Capricorn Health Tech Fund.

Dr. Dekeyser obtained his PhD in plant molecular biology at the University of Ghent and is currently professor 'innovation management' at the University of Ghent.



**Giulia DEL BRENNNA,  
Head of Unit, Food and Healthcare Industries, Biotechnology,  
DG Enterprise and Industry, European Commission**

Giulia Del Brenna has worked as an Administrator in the European Commission since April 1996 in a number of positions.

She has followed developments in European Pharmaceutical Policy since being appointed Assistant to the Director-General in May 2005. She has been appointed Head of the Unit “Competitiveness in the Pharmaceuticals industry and Biotechnology” in October 2008 (“Food and Healthcare Industries, Biotechnology” as from September 2010). Since then, she has been in charge of the dialogue with the Pharmaceuticals and Biotech industry as well as the cooperation among Pricing and Reimbursement authorities in the European Union.

**Andras DINNYES,  
Director, BioTalentum**



Prof. Andras Dinnyes has been working on embryology, cloning and stem cell biology since 1985.

He obtained his veterinary, PhD and Doctor of Sciences degrees in Hungary.

In 1991 he was a Fulbright Scholar at the Smithsonian Institution, USA.

He did post-doctoral studies in cryobiology at the Catholic University of Louvain, Belgium and in Animal Biotechnology at the University of Connecticut, USA where he has invented the solid surface vitrification (SSV) method and contributed to the generation of the first adult cell nuclear transfer cloned cows in the US.

In 1999 he worked in Japan. In 2000 he joined the "Dolly cloning team" in Roslin Institute, UK as team leader, under the guidance of Sir Ian Wilmut and succeeded in the production of the first gene knock-out lamb, and the first cloned piglet in Europe. Furthermore, he was Nuclear Transfer Consultant for Geron Corporation, USA.

In 2002 he was an OECD Research Fellow at AgResearch, New Zealand, a Visiting Professor at Kunming Institute of Zoology, Chinese Academy of Sciences, China, a NATO Senior Research Fellow at the University of Nottingham, UK and a JSPS Visiting Senior Scientist, National Institute of Agrobiological Sciences, Japan.

In 2003 he has returned to Hungary with a Wellcome Trust International Senior Research Fellowship in Biomedical Science and since 2007 he is a full professor at Szent Istvan University, Hungary on Molecular Animal Biotechnology.

Furthermore, he is invited professor at Utrecht University for 20% of his time.

He is the co-founder and director of BioTalentum Ltd, an SME very active in European research, coordinating 8 FP7 collaborative and Marie Curie projects and participating in several others in stem cell research for biomedical purposes – by now employing more than 20 researchers.

**Presentation**

"Contribution of EU funding to knowledge creation at BioTalentum Ltd"

**Ruxandra DRAGHIA-AKLI,  
Director, Directorate Health, DG Research and Innovation,  
European Commission**



Previously, Ruxandra Draghia-Akli served as Vice President of Research at VGX Pharmaceuticals (now Inovio) and VGX Animal Health.

Dr. Draghia's research activities have focused on molecular biology, gene therapy and vaccination. She is recognised as a global leader in the field of nucleic acid delivery for therapeutic and vaccination applications. She is an inventor on more than a hundred patents and patent applications.

Throughout her career, Dr. Draghia has published numerous scientific papers and reviews in the areas of electroporation, plasmid components, growth and development, immune stimulation, vaccination, health, and well-being. She served as ad-hoc reviewer for granting agencies, annual meetings for gene therapy and endocrinology societies, and scientific journals in Europe and the USA.

Dr. Draghia received an M.D. from Carol Davilla Medical School and a Ph.D. in human genetics from the Romanian Academy of Medical Sciences. Dr. Draghia also completed a doctoral fellowship at the University of Rene Descartes in Paris and a post-doctoral training at Baylor College of Medicine (BCM), Houston, Texas, USA, and served as faculty at BCM.

**Peter DROELL,  
Head of Unit, Policy Development for Industrial Innovation,  
DG Enterprise and Industry, European Commission**



Peter Dröll is in charge of Industrial Innovation Policy Development in the European Commission's Enterprise and Industry Department. In this capacity, he has co-authored the 2010 "Innovation Union" strategy and is overseeing the Commission activities on innovation analysis, benchmarking and demand side measures.

His previous positions in the European Commission include financial control of the Joint Research Centre, enforcement of EU environmental legislation, accession negotiations with Poland and coordination of the environment negotiations with all accession countries. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik.

Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. Before joining the European Commission in 1991, Peter worked as a lawyer in a German law firm.

**Ernő DUDA,**  
**President, Hungarian Biotechnology Association,**  
**President and Chief Executive Officer, Solvo Biotech**



Ernő Duda is also Co-Founder, President & CEO of Solvo Biotechnology, Hungary's largest independent biopharmaceutical company specialized in ABC-transporters and Drug Resistance. As a genuine entrepreneur, he has founded or co-founded 15 companies, including a corporate finance consulting company focused on high-tech Hungarian start-ups, and Hungary's largest online second-hand book store.

He was Vice President of the American Chamber of Commerce in Hungary in 1998 and 1999, and President of the Junior Achievement Foundation Hungary from 1997 until 2006. He has experience in teaching English language, applied economics and management studies as well, and almost 3,000 students have attended his biotech business course at the University of Szeged since 2003.

Ernő Duda is a member of the Board of Trustees of the Bay Zoltán Foundation for Applied Research, and the Board of the Hungarian Association for Innovation. He is also a regular contributor to newspapers, periodicals and other publications, and frequently holds presentations at conferences and various public events.

**Anne-Kirstine DYRVIG,  
Coordinator, Odense University Hospital**



Anne-Kirstine Dyrvig is MSc. in Public Health from the University of Southern Denmark. She is recently enrolled as ph.d. student at Odense University Hospital and University of Southern Denmark within the field of HTA and telemedicine with special focus on transferability of results across countries.

Since 2008, Ms Dyrvig has been employed in the Quality & Research/Health Technology Assessment department at Odense University Hospital & Svendborg Hospital (OUH), where she is part of the Health Technology Assessment (HTA) team. The HTA team supports the clinical departments in writing and completing mini-HTAs that are a standard tool at OUH prior to the purchase and implementation of new devices etc. The HTA team and their services are also in high demand from external organisations, which means that the team holds a leading position in not just the Region of Southern Denmark, which is the regional health authority, but also at a national level. Ms Dyrvig is a central part of the team and has worked extensively with completion of full HTA reports as well as teaching and support for the hospital departments in their work with mini-HTAs. Also, she is frequently used as a teacher in courses on systematic literature review, HTA and mini-HTA by many other organisations than OUH.

Her work not only extends to Denmark, but given her broad HTA experience, Ms Dyrvig competences are sought internationally as well. Ms Dyrvig teaches mini-HTA to other European health organisations and she plays a main role in the evaluation of telemedicine services in an ongoing EU project called RENEWING HEALTH (CIP PSP Pilot A), which involves 9 European regions and 26 different telemedicine services, where Ms Dyrvig tasks involve evaluating the effectiveness of the different telemedicine solutions in a telemedicine-adapted HTA framework based on prospective data collection.

**Presentation**

"Involving hospital staff in the uptake of new health technologies: The use of mini-HTA."

**Björn EKSTRÖM,  
President and Chief Executive Officer, Olink**



Mr Björn Ekström is President and Chief Executive Officer of Olink AB, a privately held biotech supply company based in Uppsala, Sweden. Olink AB develops enabling tools and detection technologies to the life science research and diagnostics community. The technologies are available as proprietary products and services supplied by Olink Bioscience and its licensees.

Björn Ekström has extensive experience from the biotech supply industry, including 18 years with Pharmacia Biotech (now GE Healthcare) initially as a product specialist and thereafter in leading R&D positions and last 5 years as Director of Exploratory Research. In this capacity and under his supervision several new technologies were developed that eventually were commercialized (Gyros AB, Åmic AB). In 1997, he left Pharmacia and participated in the foundation of Pyrosequencing AB (now Biotage AB), joining the company as Executive Vice President and CTO. He was deeply involved in the IPO process leading up to the listing of the Pyrosequencing AB on Stockholm Stock Exchange in 2000.

In 2003 he founded Becan, a technology and management consulting company. In 2004 he became a co-founder of Olink AB and he has since served as the President and CEO of the company.

He has served on the board of directors for several commercial companies and he is currently on the BoD of Cobolt AB, Sigolis AB and Q- Linea AB. Mr Ekström has published 6 scientific papers, contributed to 8 patents and patent applications. He has been involved in several publicly funded research projects and he has been the coordinator of an EU FP6 projects. Mr. Ekström holds an MSc in Physical Biochemistry from The Institute of Technology, Lund, Sweden.

**Presentation**

"Participation in EU projects from an SME perspective"

**Pietro FOLINO GALLO,  
Director of Medicines Utilisation and Expenditure and HTA,  
Italian Medicines Agency**



- Pietro Folino Gallo is Director of the Unit for Monitoring Pharmaceutical Utilisation and Expenditure and HTA activities at the Italian Medicines Agency (AIFA)
- He has coordinated European Commission (DG-Research and DG-SANCO) and national projects in the pharmaceutical field, with special interest in international comparison of pharmaceutical expenditure and utilisation, and has been member (2003-2008) of the European Commission DG-SANCO Working Party on Health Systems
- He has been President (2003 - 2008) of the section on utilisation of medicines of the European Public Health Association (EUPHA)
- He has been member of the Working Group on Pricing of the European Commission - High Level Pharmaceutical Forum
- He is member of the EUnetHTA JA and of the EU Network of Competent Authorities for Pricing and Reimbursement
- He is member of the Steering Group of the EU Platform on Access to Medicines in Europe
- He is Member of the ISPOR HTA Council

**Presentation**

"Access to cancer medicines"

**Máire GEOGHEGAN-QUINN,  
Commissioner for Research,  
Innovation and Science, European Commission**



Máire Geoghegan-Quinn became the European Commissioner with responsibility for research, innovation and science in February 2010. As part of her specific work responsibilities, she has been appointed by the President of the European Commission Jose Manuel Barroso to draw up a research and innovation plan for the European Union by autumn of this year. Commissioner Geoghegan-Quinn also has political responsibility for the operation of the 7<sup>th</sup> EU Research and Technological Framework Programme 2007–2013, which is the largest publicly funded research programme in the world.

Between the period March 2000 and February 2010, Máire Geoghegan-Quinn served as a member of the European Court of Auditors.

Between 1975 and 1997, Máire Geoghegan-Quinn was a member of the Irish Parliament (Dáil Eireann). In 1979, she became the first woman to be appointed as a cabinet Minister since the foundation of the Irish state and she served as a Minister with responsibility for the Gaeltacht until 1981.

Between the period 1987-1991, Máire Geoghegan-Quinn served as the Irish Government Minister with responsibility for European Union affairs. She oversaw the preparation of the Irish Presidency of the European Union in 1990, which took place in the immediate aftermath of the collapse of communism in Eastern and Central Europe. During this Presidency, she was the Irish representative at meetings of the Council of Foreign Affairs Ministers. She also chaired Ministerial meetings of the Budget, Telecommunications, Culture and Development Aid Councils.

Between 1992–1993, she served as the Irish Minister with responsibility for Tourism, Transport and Telecommunications. During this period, she supported measures to open up competition in the Irish airline sector.

Between 1993–1994, she was the Irish Minister for Justice. She was one of the negotiators of the Downing Street Declaration which was signed between the Irish and the British Governments in December 1993. This declaration paved the way to bringing peace to the island of Ireland.

Between 1997-2000, Máire Geoghegan-Quinn served as a non-executive director of both Aer Lingus and of the Ryans Hotel Group. She was a T.V presenter, a columnist in the Irish Times newspaper and she served as a part time business consultant.

She is a former member of the Governing Authority of the National University of Ireland Galway.

In 1996, she authored a book entitled 'The Green Diamond'.

Prior to entering politics in Ireland in 1975, Máire Geoghegan-Quinn qualified and worked as a primary school teacher.

**Bernard GIBIS,  
Director, National Association of Statutory Health Insurance Physicians  
Germany**



Bernhard Gibis is heading the department for service contracts and pharmaceuticals at the National Association of Statutory Health Insurance physicians (KBV) in Berlin, covering the fields of health information, evidence based health care and service delivery design.

He qualified as an MD in Germany and specialized in gynaecology and obstetrics, in addition to which he holds a Masters degree in Public Health.

His expertise is in the field of evidence based health care covering in particular the areas of evidence informed decision and policy making (i.e. guidelines, health technology assessment), quality assurance (i.e. quality indicators, quality management) and knowledge management (i.e. communities of practice, organizational support tools).

He is a member of acknowledged societies of the field, member of the scientific boards of respective journals and serves as advisor to national and international research projects. His professional affiliation has been with various national and international organizations such as the Alberta Heritage Foundation for Medical Research and the World Health Organization.

**Presentation**

"How much will it cost/how much will we pay? Pricing and reimbursement"

**Iain M. GILLESPIE,  
Head of Science & Technology Policy Division,  
Directorate for Science, Technology and Industry, OECD**



Iain Gillespie is Head of the Organisation for Economic Cooperation and Development's (OECD) Science and Technology Policy Division. The Division works with the 30 OECD member countries as well as some 70 non-members to develop international consensus on a wide range of scientific and technological policy issues, including those related to emerging technologies such as nanotechnology and biotechnology. The Division is also responsible for OECD's work on innovation policy and concomitant country studies.

Iain was previously Head of the OECD's Biotechnology Division, from its creation in 2005 to its incorporation in the current Science and Technology Policy Division in 2009. Iain worked in academia (UK and Middle East) and in the biotechnology industry (Agricultural Genetics Co Ltd, Cambridge) before joining government service in 1991. He held policy posts in the UK Departments of the Environment, of Health and of Trade and Industry as well as in the Cabinet Office where he ran a small policy unit in support of the UK's Chief Scientific Advisor (the now Lord May) developing advice on issues as diverse as climate change, human cloning, the use of scientific advice in policy making and risk. Just before joining OECD, Iain ran the highly successful Pharmaceutical Industry Competitiveness Task Force (PICTF), reporting to the UK Prime Minister.

Iain is a scientist by training with a PhD in Microbiology. He also holds an MA in International Relations and European Politics and an MBA with specialisms in knowledge management and innovation. He was educated at the Universities of Edinburgh, London and Kent at Canterbury, as well as the Open University in the UK, and prior to that at George Heriot's School in Edinburgh. Iain is a member of the GlobalScot network. He is married with a son.

**Audrey GOOSEN,  
Policy Officer, Knowledge transfer:  
University-industry relations, Innovation Policy Unit,  
DG Research and Innovation, European Commission**



Audrey Goosen is a policy officer at the European Commission, DG Research at the unit Innovation Policy. She studied business administration at the Erasmus University in Rotterdam, with a specialization in innovation. After which she worked in the field of innovation at KPMG, followed by the healthcare sector and the Association of Universities. Before joining the European Commission last year, she worked for the Dutch Ministry of Economic Affairs, Agriculture and Innovation, within the Directorate Innovation. She won among others the Wings of Excellence Award, McKinsey at the ISC Conference, St Gallen-Harvard and wrote several articles on creativity and innovation.

**Frank HEEMSKERK,**  
**founder and CEO of Research & Innovation Management Services bvba**



After an academic background of 15 years in neurochemistry and pharmacology in the Netherlands (U Utrecht), USA (National Institutes of Health) and France (U Pasteur), Dr Frank Heemskerk joined a small Bio-pharmaceutical company in Belgium (Tibotec-Virco), world leader in R&D for HIV drug discovery, development and diagnostics. As Director Research Coordination & Funding he was responsible for the Co-ordination, Management and Administration of all publicly funded Research projects in the company and the Business Development aspects of the external Research collaborations. In this position he supported the growth of the company from 28 to more than 250 employees over 4 years, through a merger, multiple private placements and finally an acquisition for 500 M€ by Johnson & Johnson. In 2002 he started Research & Innovation Management Services ([www.RIMSinternational.eu](http://www.RIMSinternational.eu), *Belgium*) as an independent service provider focused on building Open Innovation networks to bring Knowledge from Academia to the Market. The company has now access to a global network of >2700 life science organizations, is active in Europe, Latin America, Africa and India and is core partner in a number of EU projects (FP7, ACP, see website).

His leadership positions in EARMA ([www.earma.org](http://www.earma.org), a network of research managers in hundreds of academic and industrial European organizations) and co-founding of ProTon Europe ([www.protoneurope.org](http://www.protoneurope.org), now the largest European association of University Technology Transfer offices of universities) are valuable to assess trends across Europe and beyond. He serves regularly as a consultant and Expert Evaluator to the European Commission, the Flemish government and European organizations (e.g. Advisory Board [www.mariecurie.org](http://www.mariecurie.org)). He has been involved in >38 EU projects since FP4 and serves on the Board of several start-up companies. This way he combines 15 years of academic research with >14 years in industry.

- Past-President European Association of Research Managers & Administrators
- Member Sounding Board for small actors on FP7 Simplification measures (DG RTD, European Commission) (2006-2008)
- Advisory Board member of Celtic Catalysts Ltd (*Ireland*), Eyytoo Bioscience SL (*Spain*) and formerly in Pharmaneuroboost NV (*Belgium*) and Beocare Ltd (*Ireland*)
- Supervisory Board member of UniCRIS GmbH (*Switzerland*).

**Tony HICKSON,  
Managing Director of Technology Transfer, Imperial Innovations**



Tony Hickson (MSc, MBA) joined Imperial Innovations in early 2002 and is Managing Director of the Technology Transfer team.

Tony has fifteen years of technical and commercial licensing experience in bioscience companies including Wellcome Group R&D, Murex Biotech (which was acquired by Abbott Laboratories) and Kalibrant Ltd.

**Stéphane HOGAN,**  
**Head of Coordination Unit, Directorate Health,**  
**DG Research & Innovation, European Commission**



Stéphane Hogan is currently Head of the Coordination Unit in the Health Directorate of DG Research & Innovation. His unit is responsible for planning and coordination of Health research in the EC's 7<sup>th</sup> Framework programme, which foresees €6 billion in grants for Health research over the period 2007-2013. His unit also addresses cross-cutting issues such as industry participation (in particular SMEs), international cooperation, ethics and communication.

Prior to that he spent several years in research in Ireland and Belgium, then worked in journalism and in corporate communications in France, before joining the European Commission in Brussels in 1996.

Stéphane holds a degree in science (Genetics) and an MSc in Biotechnology from Trinity College Dublin (Ireland), as well as an MBA from The Open University (UK).

**Philippe JACON,  
Director General, EDMA**



Newly appointed Director General of EDMA, Philippe spent most of his career with BD (Becton Dickinson and Co) in various positions and locations.

Most notably, he was Worldwide President of BD Diagnostics-Diagnostic Systems, Worldwide President of BD Diagnostics - Microbiology Systems, VP/GM Europe BD Medical - Diabetes Care. Prior to these roles, Philippe held positions of increasing responsibility in BD Medical-Pharmaceutical Systems in Europe and subsequently in the US where he was the VP/GM for the business. Philippe started his career at BD as a Sales Representative in France for BD Biosciences.

During his time in Baltimore, MD, Philippe played an active role in the community. He served on the board of the University of Maryland BioPark and the Greater Baltimore Committee. He was also appointed by Governor Martin O'Malley to the Maryland Life Sciences Advisory Board.

Philippe has a Microbiologist Engineer degree from the Université de Bretagne Occidentale in France.

**Panos KANAVOS,  
Director, Health and Department of Social Policy,  
London School of Economics**



Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Senior Lecturer in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Head of the Medical Technology Research Unit (MTRU) at LSE Health. Panos is Visiting Professor at the University of Lausanne, Switzerland and Visiting Senior Lecturer at the London School of Hygiene and Tropical Medicine (LSHTM). He is an Economist by training, currently coordinates the Programme in Health Policy Planning and Financing at LSE and teaches Health Economics, Pharmaceutical Economics and Policy, Health Care Financing, and Health Systems Performance Measurement.

Panos leads the activities of MTRU, which is a research unit comprising 14 researchers within LSE Health and concentrates on interdisciplinary and comparative policy research on medical technologies. The unit has a number of research streams as follows:

- *the economics of medical technologies, in particular, medicines and medical devices;*
- *Prescribing, appropriateness and quality of care;*
- *Access to medical technologies in developing and transition economies; and*
- *Disease management and policy effectiveness medical technology.*

Panos has acted as an advisor to a number of international governmental and nongovernmental organizations, including the European Commission, the European Parliament, the World Bank, the World Health Organization, the Organization for Economic Co-operation and Development, the American Association for Retired Persons, and Ministries of Health of over 21 transition and developing countries.

**Alastair KENT,  
Chairman, European Platform for Patients' Organizations, Science and Industry  
(EPPOSI)**



Alastair Kent is the Chair of the European Platform for Patient Organisations, Science and Industry (EPPOSI). This is a multi-stakeholder platform for the exploration of aspects of common concern in European science and health policy. He is the President of the European Genetic Alliances Network (EGAN), which brings together national alliances of patient organisations supporting those affected by serious and life limiting genetic disorders, and the Director of Genetic Alliance UK the British patient alliance. He has been a patient advocate for over 20 years, and was recently awarded an OBE for services to healthcare in the UK.

**Presentation**

"A Multi-Stakeholder Approach to Sustainable Innovation in Health Care"

**Nevenka KREGAR VELIKONJA,  
Director, Educell**



Nevenka Kregar Velikonja, PhD, BSc biol. is a director of the company Educell since 2002 and leader of company's research group, working on R&D of human primary cell cultures, stem cells and tissue engineered cell products for clinical applications.

She has 15 years of experience with research work on field of molecular biology and tissue engineering.

She was involved in 12 national and 2 EU R&D projects, she was leader of 3 national projects and coordinator of work packages in EU projects. She is a mentor to three young researchers PhD students.

Dr. Kregar participated in establishment of Cell and tissue engineering society of Slovenia ([www.dctis.org](http://www.dctis.org)), and is secretary of the society. She was member of organising and scientific committees of 2 international and several national symposia, organised by the Society.

Her scientific activities resulted in publication of 9 SCI cited scientific articles in last 5 years. Her whole bibliography includes 90 publications. She co-edited scientific monography Tissue Engineering and Cartilage Repair, Ljubljana 2007,

As scientific expert dr. Kregar participated in evaluation process in EU call within Marie Curie program as well as in national calls.

**Presentation**

"Entrepreneurial possibilities in field of cell and tissue engineering"

**Torbjörn KRONANDER,  
CEO, Sectra**



Dr Torbjörn Kronander, MSEE, Ph.D. MBA, president and founder of Sectra Imtec AB, with its business in digital medical imaging.

TK has a MSEE with in Medical technology, and a Ph.D. in Information Theory/Image Coding, both from Linköping University, Sweden. He has been author or co-author of more than 30 scientific papers in Image Data Compression, Image Processing and Medical Imaging.

After his Ph.D. he started up Sectras medical division. And Sectra has since grown to be a publicly traded €100M company, customers in more than 50 countries and 550 employees. He has furthermore an MBA from Stockholm School of Economics.

In 2000 Sectra co founded a new business with researchers from CERN/the Royal Institute of Technology in Stockholm. This resulted in Sectra Microdose Mammography which gives screened women half the radiation, at the same or better cancer detection than any other system. Dose is a very important factor when screening large amounts of healthy women. Sectra has subsequently received a grant from EU, HiRex, Intended to provide safer and better mammography for future European women.

In 2001 Torbjörn Kronander co-founded a research center, CMIV, with Linköping university and the county council of Östergötland in Sweden. CMIV (Center for Medical Image science and Visualization) combining technological and medical research with clinical practice. CMIV is located in the center of Linköping University Hospital. CMIV has become a large success and it is today producing more dissertations in diagnostic imaging than the rest of Sweden combined.

Torbjörn Kronander is furthermore the father of four sons, a reservist in the Royal Swedish Navy, a devoted sailor, a pilot of most things that fly and a full member of the Swedish Royal Academy of Engineering Sciences.

**Presentation**

"Saving Europe's countries money by finding expensive disease early"

**Ludovic LACAINE,  
Director, Health Care Biotechnology Europabio**



Ludovic Lacaine is Director of Healthcare at EuropaBio, the European Association for Bioindustries.

Previously Ludovic worked at Brandtectonics Europe (a Chandler Chicco Companies - CCC) based in London providing market access solutions to small molecule, biopharmaceutical and medical device businesses. Prior to Brandtectonics Europe, Ludovic led pan-European PR and policy programmes in oncology and HIV/AIDS at Weber Shandwick Brussels. His policy work at Weber Shandwick also included the development of institutional stakeholder programmes, policy influencing and political landscape mapping.

Thanks to his pro bono collaborations with the British Medical Association's liaison office (BMA) in Brussels, Ludovic also has an insight into European healthcare professional issues. Moreover, Ludovic has extensive experience in building multidisciplinary alliances, managing KOLs and media relations across the EU 27.

Ludovic has an MSc in Social Geography, obtained in two universities (Caen, France and Oulu, Finland) and a Masters degree in European affairs from the University of Barcelona.

Ludovic is multilingual in French, Spanish and English.

**Guy J. LEBEAU,**  
**Chairman, European Medical Technology Industry Association (Eucomed)**



Guy J. Lebeau, M.D., Company Group Chairman, Johnson & Johnson oversees the MD&D business for Europe, Middle East and Africa. This diverse business with more than 15,000 employees comprises seven franchises and has a combined income in excess of \$6 billion. In addition to his leadership role within Johnson & Johnson, Dr. Lebeau is actively involved in Eucomed - Europe's regional trade association for the medical technology industry – and was named Chairman of the Board in October 2007.

Dr. Lebeau has broad international experience in business management and medical technology. He joined Johnson & Johnson in 1991 in research & development and later moved to medical devices business units where he held positions of increased responsibility in sales and marketing.

More recently Dr. Lebeau was named Worldwide President, Biosense Webster, the electrophysiology business unit, in 2001. In 2003 Dr. Lebeau was appointed Worldwide President of Cordis Corporation. In 2004 he was named Company Group Chairman for the Cordis Franchise, the cardiovascular business unit.

Prior to joining Johnson & Johnson, Dr. Lebeau served as Assistant Professor of Surgery in the Digestive Surgery Department (Organ Transplant Unit) at the University of Rennes (France) School of Medicine. Dr. Lebeau graduated from the University of Rennes (France) and Paris (France) and holds Master's degrees in cellular biology and transplant immunology. He is also certified in general surgery. Dr. Lebeau has authored journal articles and book chapters in the fields of hepatology, liver transplant and general surgery.

**Julianna LISZIEWICZ,  
President, Chief Executive Officer, Vice-President of Research,  
Genetic Immunity**



Dr. Julianna Lisziewicz co-founded Genetic Immunity in 1998 and has served as the President and Chief Executive Officer of Genetic Immunity since its founding.

In 1994, Dr. Lisziewicz co-founded the non-profit Research Institute for Genetic and Human Therapy (RIGHT) and directed its research and business affairs in the USA. RIGHT was focusing on the treatment of HIV/AIDS from multiple perspectives: virology, molecular biology, immunology and medicine. From 1990 to 1995, she was Head of the Antiviral Unit in the Laboratory of Tumor Cell Biology at the National Cancer Institute of the NIH in Bethesda, Maryland. While at NIH, she discovered and developed antisense oligonucleotide therapy and gene therapy for HIV/AIDS treatment.

In 2005, she was appointed as the Marie Curie Chair at the Semmelweis University Budapest. She received her Ph.D in molecular biology from the Max-Planck Institute (Goettingen, Germany) and two Masters of Science in Chemistry and Biochemistry from the Technical University (Budapest, Hungary). She has co-authored over 100 peer reviewed scientific publications.

**Presentation**

"Entrepreneurship matters – the role of innovative SMEs"

**Joël JEAN-MAIRET,  
Managing Partner, Ysios Capital Partners**



Joël Jean-Mairet is co-founder partner of Ysios Capital Partners, a Barcelona-based venture capital firm with €70 Mio under management providing private equity financing to early, mid - and late-stage biotech and medtech companies. Joël oversees all operations including management, strategy and standard operations.

Joël is currently chairman of Cellerix, a Madrid-based adult stem cell therapy company that has raised over €54 Mio in equity in the last years, and was board observer of BioVex, a company acquired by Amgen early this year for up to \$ 1bn.

Previous to Ysios, Joël co-founded GLYCART Biotechnology AG (Zürich, Switzerland) in March 2001 and was Chief Executive since inception. He raised over €15 Mio in three rounds of financing for GLYCART before the company was sold to F.Hoffmann-La Roche Ltd in July 2005 for € 152 Mio in cash.

Joël received a PhD in cell biology and immunotherapeutics from the Swiss Federal Institute of Technology in Zürich. He was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for GLYCART, including the Wall Street Journal Europe Innovation Award in 2001.

The GLYCART-Roche transaction was lauded by European Venture Capital magazine as the "Venture Deal of the Year" (2005) in the Healthcare category.

**Nathalie MOLL,  
Secretary General, EuropaBio**



After graduating with Honours in Biochemistry and Biotechnology from St Andrews University, Scotland, Nathalie worked in the biotechnology and food policy area for the European Crop Protection Association and then for the Italian National Biotech Association, Assobiotec and Dompe' Farmaceutici S.p.A, dealing with the implementation of EU biotech legislation at National level.

In addition, Nathalie has spent almost a decade representing the European Biotechnology Industry through EuropaBio in the posts of External Relations Manager, Director for Strategic Policy, Director of the Healthcare Biotech sector, Director of the Agricultural Biotech sector and most recently as Secretary General since April 1<sup>st</sup>, 2010.

In the course of her career, Nathalie has focused on improving awareness of the importance and benefits of biotechnology for Europeans and has worked, together with the industry, regulators and stakeholders, towards developing a more supportive legislative framework for the industry and related sectors.

**Stefan NARDI-HIEBL,  
Head of Siemens Healthcare Consulting, Siemens AG,  
Siemens Healthcare Consulting**



Stefan Nardi-Hiebl studied Computer Science at the University of Applied Science Regensburg and obtained a post-graduate Masters degree in Management with Focus on Healthcare from the London School of Economics and Political Science as well as an Executive MBA from the European School of Management and Technology. Prior his studies he accomplished an apprenticeship as a paramedic.

In 1998, he became Project Manager for a research project for Telemetric Technologies in Disaster Medicine and Civil Defense at the University of Regensburg. In 2000 he joined Siemens with various functions in Healthcare and Seed Capital Finance. In 2005 he joined Siemens Healthcare Consulting specializing in Strategy Development and Economics. In this period he led several health-economic studies for a pharmaceutical client in Germany, Netherlands, Sweden and Finland. From 2007 to 2008 he supported the set-up of Siemens Healthcare Consulting in the United States and was in charge of Health Economics and Strategy projects. In 2009 he has been promoted to Head of the Practice Group Clinical Advisory. His responsibilities included serving clients on the hospital, regional and national level to improve the medical and economic outcome, developing methods and tools to assess the impact of changing factors in Healthcare and acting as an advisor for the Siemens Top Management in regard to such questions. Since October 1, 2010 he is leading Siemens Healthcare Consulting.

He co-authored several articles about health economic studies in cooperation with the pharmaceutical industry.

**Daniel NELKI,  
Head of Legal and Operations, Wellcome Trust**



Dr. Daniel Nelki is Head of Legal & Operations in Technology Transfer at the Wellcome Trust. Daniel obtained his Ph.D in 1987 from the University of London and went on to conduct postdoctoral research in mouse molecular genetics at King's College, London. He obtained a Diploma in Law in 1991 and, following completion of his professional solicitor's qualifications, practised with the international law firm, Baker & McKenzie, where he gained experience in a wide range of law and specialised as an intellectual property lawyer. Daniel joined the Wellcome Trust in 1995 and played a key role in planning and structuring the Technology Transfer group, from his uniquely multi-faceted perspectives which embrace the Trust's activities, intellectual property and charity law, and the commercial exploitation of fundamental research. He has also been awarded a Masters in Law (LL.M.) for a thesis on the ownership of human genes and tissue.

**Presentation**

"Translational Research Funding at the Wellcome Trust"

**Anders OLAUSON,  
President, European Patients' Forum**



©Sylvain Gouraud

Anders Olauson was involved in the founding of the Agrenska Centre in 1989. He served as director until 2004 and since then has been chairman and chief executive officer. He is responsible for establishing The Agrenska Virtual International Academy, a research centre for rare disorders.

Anders is particularly concerned with the impact of rare conditions on children and their families. His work involves contact with both national and regional legislative bodies on the subject of rare disorders. He is also in contact with representatives of hospitals, education and labor unions as well as other key players in the field of rare diseases.

Anders has been a member of the board of Eurordis from 1999 until 2010, and was president from 1999 to 2001. He currently represent Eurordis as a member of the board of the European Patients' Forum (EPF). He has been president of EPF since June 2005.

Anders represented EPF in both steering committee and at The Pharmaceutical Forum, which was established by DG Sanco and DG Enterprise in 2005.

Agrenska was in 2005 appointed member of ECOSOC within United Nations, with "special consultative status".

Since 2006 Anders is a member of the advisory group for Health Research within DG Research. In 2005 Anders was accepted as a researcher within the PhD program at Gothenburg University.

The Swedish Government appointed Anders September 15<sup>th</sup> 2008, to be a member of the Advisory Council at The National Board of Health and Welfare.

Anders Olauson received HM The King of Sweden's Medal for his valuable contributions in the field of disability. Anders was presented with the King's medal 8<sup>th</sup> size, with the Seraphim Ribbon at the Royal Palace in Stockholm, the 28<sup>th</sup> of January 2010.

**Andrea RAPPAGLIOSI,**  
**Co-chair HTA Task Force,**  
**European Federation of Pharmaceutical Industries and Associations,**  
**Vice President, GlaxoSmithKline**



Born in Rome, Andrea Rappagliosi received a law degree from the University of Rome “*La Sapienza*” and completed a post-graduate Masters at the *Istituto Superiore dei Studi Legislativi* (ISLE) from which he obtained a “Legislative Consultant Diploma”.

He began his career in the early eighties, first in the Italian Government as a member of staff for the State Undersecretary of the Treasury, then for the Italian Senate focused on drafting of legislative texts, comparative legal studies and public budget analysis.

In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team. In 1999, he returned to Serono International, today Merck Serono International, as Vice President Health Policy & Market Access Europe.

In April 2009, Andrea joined GlaxoSmithKline as Vice President European Government Affairs & Head of Brussels Office.

- On June 2009, he has been appointed Chair of the Board of EuropaBio, the European Association of Bioindustries.
- On June 2010, he has been appointed co-Chair of the HTA Task Force of EFPIA, the European Association of the R&D pharmaceutical Industry.
- From 2005 to 2008, he has been member of the European Commission High Level Pharmaceutical Forum representing EuropaBio, the European Association for Bioindustry.
- He sits on the Board of the Foundation of the European Platform for Patients Organizations, Science & Industry (EPPOSI).
- He is member of HTAi (the International Society of Health Technology Assessment) and member of its Policy Forum.
- He has been Industry representative at the EMEA/COMP (European Medicines Evaluation Agency/ Committee for Orphan Medicinal Products) Working Group with Interested Parties in the first two terms 2000 to 2005.
- He is member of the British Institute of International and Comparative Law and is a member of the Editorial Board of the Journal of Commercial Biotechnology.

**John R. RIDGE,  
Director of Reimbursement Services and Health Economics,  
Roche Tissue Diagnostics**



John R. Ridge is responsible for developing and implementing strategies that will secure reimbursement and funding for Roche Tissue Diagnostic's products around the world. Formerly, he was the National Director of Managed Care and Reimbursement for diaDexus, Inc. and was responsible for interactions with public and private payors on coverage, coding and payment of diaDexus products. John R. Ridge has over 15 years of experience working with stakeholders involved in the adoption of new technologies including Congress, State Legislatures, the American Medical Association, managed care organizations, technology assessment agencies and government payers. John Ridge's primary focus is managing the complexities of negotiating successful coverage from insurers for new products and for solving reimbursement and funding dilemmas faced by new medical technologies.

John Ridge has authored articles on coding, coverage and payment issues and is often sought after to speak at conferences on reimbursement, health policy and governmental affairs issues. He also founded the National Association of Healthcare Reimbursement Professionals and serves on the Editorial Board Advisory Board of the Personalized Medicine Journal.

John Ridge graduated from Florida State University with a bachelor's and master's degree in Interdisciplinary Social Sciences.

**Presentation**

"Healthcare System Pressures: A Threat to Innovation"

**Andrzej RYŚ,  
Director in Directorate C, Public Health and Risk Assessment,  
DG Health and Consumers, European Commission**



Andrzej Ryś is a medical doctor graduated from Jagiellonian University, Krakow, Poland. He specialized in radiology and public health. In 1991 he established School of Public Health (SPH) at the Jagiellonian University and he was the SPH's director till 1997. From 1997-1999 he took up the post of director of Krakow's city health department. In 1995 – 1999 he was the Polish director of the “Harvard-Jagiellonian Consortium for Health” – a project focusing on local governments' role in health care. In 1999 – 2002 he became the deputy Minister of Health in Poland and developed a new system of emergency medicine and new education system for nurses. He was a member of the Polish accession negotiators team.

In 2003 he established and ran as a director, the Center for Innovation and Technology Transfer at Jagiellonian University, Krakow, Poland. He was also director for development of Diagnostic Ltd., executive director of the Polish Association of Private Health Care Employers and chief editor of the Journal "Health and Management". He joined the European Commission in June 2006.

**Robert-Jan SMITS,  
General Director,  
DG Research and Innovation, European Commission**



Robert-Jan Smits is Director-General of DG Research and Innovation. His previous assignment was Deputy Director-General of DG JRC where he was responsible for Programmes and Stakeholder Relations, Resource Management, and three Institutes, being the Institute for Energy, the Institute for Environment and Sustainability and the Institute for Prospective Technological Studies.

Before that Mr. Smits was Director for the European Research Area: Research Programmes and Capacity at DG RTD, where his responsibilities included: Joint Programming, coordination of national research programmes, cooperation with intergovernmental research organisations (EIROforum, EUREKA, COST), Research Infrastructures, Regions of Knowledge, Research Potential and the relations with the European Investment Bank (EIB).

Robert-Jan Smits was born in 1958. He has degrees from Utrecht University in The Netherlands, Institut Universitaire d'Hautes Etudes Internationales in Switzerland and Fletcher School of Law & Diplomacy in the United States of America.

**Christian J. SUOJANEN,  
Head of Life Sciences, Valor Management S.A.  
& Co-Chairman, Tech Transfer Summit Initiative**



Christian is a strategic adviser to biotechnology companies, Venture Capital funds, and government agencies. With a focus on Europe, North America and the BRIC countries, his primary specializations are in licensing, strategic development, fund-raising, and capital formation, selectively accepting a small number of mandates which he supports closely.

He served in a turn-around role as Secretary General and Executive Board Member of Europe's largest biotechnology association, and maintains an extensive network of close contacts with senior life science investors, industry executives and policy makers across Europe and internationally. Christian was instrumental in growing a start up into the leading pan-European provider of investment and partnering initiatives for VCs and entrepreneurial tech and biotech companies, launching major European initiatives for VC investment into biotechnology, and later industrial biotechnology. He currently co-chairs the Tech Transfer Summit Initiative, the leading international platform for bringing tech transfer officers together with senior industry licensing executives and investors to discuss best practices and improved models for collaboration and licensing.

Christian serves on several boards and committees related to biotechnology, innovation, and access to finance, was Founding President of the fastest growing country committee of Democrats Abroad and served as Co-Chairman of international fundraising for the DPCA.

He is fluent in 3 languages and holds degrees in business, political science, and an MA in International Relations & Economy.

**Miklós SZÓCSKA,  
Minister of State for Health,  
Hungarian Presidency of the Council of the European Union**



Dr. Miklós Szócska is Minister of State for Health at the Ministry of National Resources of the Republic of Hungary since June 2010.

Dr. Miklós Szócska graduated at Semmelweis University of Medicine in 1989. His interest in the management of health services organisations emerged in the late '80s when he was a student president elected from the opposition.

After graduation, he and his colleagues initiated the creation of the Health Services Management Training Centre. Since then Dr. Szócska has leading responsibilities in the development of the Centre as an institution and the development and implementation of its training programmes. Between 1995, the official creation of the Centre and June 2000, he was responsible for the every day operations as deputy director. In June 2000 he has been appointed as acting director of the Centre, of which he became the director in October 2009. Next year, in 2010 he has been appointed as dean of the Faculty of Health and Public Administration of the Semmelweis University in Budapest. He also had critical role in establishing the Centre's international relationships and recognition. At present, the Centre also serves as the Partner Institute of the World Bank Institute for its Flagship programme on health reform and sustainable financing. He serves on the boards of the European Health Management Association and the European Health Property Network.

The Centre is the Hungarian representative in the European Health Property Network, the organisation that aims the renewal of European health infrastructure investment strategy.

His research activities cover various domains of health management and policy. His recent research projects address the critical aspects of management of change, migration of health professionals and the implications of social network studies on the organisation of health care systems.

He holds a Master of Public Administration degree from John F. Kennedy School of Government at Harvard University, and a Ph.D. from the [Semmelweis University](#) in the field of change management.

Among other public service duties, Dr. Miklós Szócska was member of the Supervisory Board of the National Health Insurance Fund in 1992-1993, elected by National Parliament.

**Presentation**

"Health sector modernisation and innovation from governmental perspective"

**Antonio TAJANI,  
Vice President,  
Commissioner for Industry and Entrepreneurship**



For 14 years, from 1994 to 2008, Antonio Tajani was a Member of the European Parliament. In 1999 he was chosen as the leader of the Forza Italia party in the European Parliament and elected to the Presidency of the European People's Party-European Democrats in 1999.

During his 15 years of parliamentary activity he took part in many committees (Foreign Affairs, Constitutional Affairs, at the time chaired by the President of the Republic Giorgio Napolitano, Transport and Tourism, Fisheries, Security and Defence).

As a journalist, Mr Tajani has worked as a parliamentary reporter, head of the RAI 1 radio news and chief editor of the Rome edition of 'Il Giornale', among others. He has a law degree from La Sapienza University in Rome.

He was appointed to the Commission in 2008, starting with the transport portfolio and then taking charge of Industry and Entrepreneurship in February 2010 as Vice President.

Antonio Tajani was born on 4<sup>th</sup> August 1953 in Rome. He is married and has two children.

**Cécile THARAUD,  
CEO, Inserm transfer, Vice-President Association of European Science and  
Technology Transfer Professionals (ASTP)**



Dr. Tharaud joined Inserm in 2005 with a mission to reorganise technology transfer activities. In 2006 she was appointed CEO of Inserm Transfert, Inserm's private affiliate dedicated to all knowledge transfer activities.

Dr. Tharaud previously had a ten-year career in the pharmaceutical and biotechnology industries.

In 1993 she joined the French affiliate of Glaxo (now GlaxoSmithKline) as a Manager of New Product Strategy, before moving to the French affiliate of SmithKline Beecham in 1995 as Manager of Business Development. At SmithKline Beecham, Dr. Tharaud developed the business development function in France and actively evaluated product and technology licensing opportunities.

In 1996, Dr. Tharaud joined Genset, a listed genomics company, as Director of Patents and Licensing. She was responsible for designing and executing the Company's intellectual property strategy. In 1999, Dr. Tharaud became Vice President, Operations. In 2001, Dr. Tharaud joined the transatlantic functional genomics company Valigen as Chief Operating Officer. At Valigen, Dr. Tharaud managed the integration of the 3-way merger that created this 170-employee company.

From 2002 to 2004, Dr Tharaud run interim management positions for biotech companies, as well as consulting missions for venture capital firms. She worked for Biosciences Managers Ltd.

Dr. Tharaud received an MBA from INSEAD, a PhD in molecular genetics and immunology from the Institut National Agronomique, and an MSc from the Ecole Polytechnique. Dr. Tharaud has also completed an advanced education course at the Centre of the Advanced Study and Research on Intellectual Property at the law school of the University of Washington, Seattle, USA.

### **Presentation**

“Experience of a seed fund linked to a public research organization”.

**Patrick TRICOLI,  
Scouting & Partnering International, Sanofi Aventis**



Before joining the group in 1991 as a project manager in pharmacotoxicology, Patrick Tricoli was a researcher within the CNRS laboratory in 1986 where his main focus area was neuropharmacology and then within the medical research division of Lederle Laboratories (USA), in 1989.

In 1996, he joined the company's headquarters in Paris to head up the Promotion of Research and Technology and became, in 2002, Director of Corporate Promotion of Innovation. After 2004, he was Director of Valorization & Innovation for sanofi-aventis.

From 2007 to 2009, he was Global Deputy Head of Partnering and Innovation Department.

In March 2009, he has been appointed Head of Access to Innovation Europe in 'R&D External Innovation' organization. Patrick is also member of the IMI governance task force and responsible for IMI global office for sanofi-aventis.

Patrick Tricoli is a doctor in Pharmaceutical Sciences; has a Masters in Pharmacology and an Executive MBA.

**Piyush UNALKAT,  
Principal, Transaction Relationship Management  
(Technology Transfer), European Investment Fund**



Currently a Principal at the European Investment Fund (EIF), Piyush has represented EIF on the Advisory boards of equity funds across Europe. He has originated and executed transactions across a variety of sectors and segments from Lower Mid-Market to Venture Capital and Technology Transfer. He is now involved with launching Technology Transfer & Innovation-related initiatives across Europe. Prior to EIF, he was Head of Corporate Development at the Genetrix Group, a holding for early-stage Life Science companies (including Cellerix – stem cell company), based in Madrid. Prior to that he was an Investment Manager at Spark Ventures (early-stage VC) in Madrid/London, an Associate at Dresdner Kleinwort (Madrid/London) and a Corporate Finance Analyst in the Asia Pacific team of Barclays in London.

He holds a PhD in Biotechnology (Protein Structure) from King's College London, an International MBA from the Instituto de Empresa (Madrid) and a Bachelor's and Master's Degree in Chemistry/Toxicology undertaken at the Universities of Cardiff (Wales) and Karlsruhe (Germany). He is also an Associate Professor at the Instituto de Empresa Business School (Madrid).

**Presentation**

“EIF Experience with Fostering Technology Transfer Partnerships”

**Onno VAN DE STOLPE,  
CEO, Galapagos**



Onno van de Stolpe (CEO) founded Galapagos in 1999 and has grown the Company to its current level of over 800 employees. Galapagos is an integrated drug discovery company with a number of internal programs and two service divisions BioFocus and Argenta. For its internal programs, Galapagos has GSK, J&J, Roche and Servier as alliance partners. In these programs Galapagos is responsible for delivering clinical molecules after which the partner has certain licensing options. Before Galapagos, Onno established the European operations for Molecular Probes Inc. He started his professional career in 1987 as Manager Business Development at MOGEN, an agricultural biotech company.

Onno received his Master's degree in Virology, with honours, from the Agricultural University in Wageningen, the Netherlands.

**Presentation**

"Achieving the unachievable"

**Jacques VISEUR,**  
**Managing Director, Eurotop Cooperation Partners**



Dr Jacques Viseur is Managing Director at ***EuroTop Cooperation Partners***, a Brussels-based management and communication company specialising in innovation, research, and international industrial and scientific cooperation projects ([www.eurotop.be](http://www.eurotop.be)).

Jacques Viseur is currently Project Manager of Europe INNOVA Communications, an initiative of the European Commission's DG Enterprise and Industry ([www.europe-innova.eu](http://www.europe-innova.eu)).

Jacques Viseur is also coordinator of the **KAPPA-Health** project ([www.kappahealth.org](http://www.kappahealth.org)), a Support Action in the FP7 Health theme that sets out strategic approaches to support bio-medical research intensive SMEs in the exploitation of the results generated from their participation in European Union Framework Programmes 6 and 7 (FP6 and 7) for research and technological development.

Jacques Viseur has more than 20 years of extensive experience in innovation and scientific cooperation and implementation at international, national and regional levels, and is the author of several publications in the field of innovation and technology.

In previous years, he has been appointed to senior positions in several research networks, sectoral federations and European business organisations. Jacques has been Secretary-General of the ESNBA – the European Secretariat of the National Bio-Industries Association, which is now merged with EuropaBio, and Secretary General of the Belgian BioIndustries Association (1996-2005). Jacques Viseur is currently in charge of the communication and coordination of research group activities in international co-operation projects for the European Commission's DG Research and DG Enterprise and Industry, such as KAPPA-Health, Fir for Health ([www.fitforhealth.eu](http://www.fitforhealth.eu)), Euro-THYMAIDE ([www.eurothymaide.org](http://www.eurothymaide.org)) and NCPs-National Contact Points in Bio-Economy and Healthcare ([www.ncp-bio.net](http://www.ncp-bio.net)).

Jacques Viseur holds an MSc in Agronomy and a PhD in Biotechnology from the FSA Gembloux University, Belgium. He is inventor of a patent in plant biotechnology and a communication tool ([www.xtranet-isa.com](http://www.xtranet-isa.com)).

**Presentation**

"From idea to market: Ingredients of Success for SMEs in Health research and innovation" - Evidence from case studies"

**Simon VRHUNEC,  
Director, University Medical Centre Ljubljana**



Director of University Medical Centre Ljubljana, the biggest hospital in Slovenia and one of the biggest in region with more than 100.000 inpatients and more than 750.000 outpatient visits for all medical specialties. The program is performed with 7.600 employees of which more than 1.200 MD's and 3.500 nursing staff.

Previously at Health Insurance Institute of Slovenia (HIIS) as a Director of Regional Unit (RU) Ljubljana. RU Ljubljana is the biggest regional unit of HIIS with 180 employees. RU is responsible for one third of all Slovenian citizens and almost forty percents of all public resources spent for health care in Slovenia. RU is contracting more than four hundred health care providers including University Medical Center Ljubljana.

During that period also a member of consulting team on the WB sponsored project Audit of Health Care Institutions Contracting with HIF in Serbia.

He was also a State Secretary on Ministry of Health of Republic of Slovenia. Areas of work were healthcare system financing, resources allocation and organization of the healthcare system. In 2003 a co-author of Slovenian healthcare reform with which in Slovenian health sector, especially at healthcare providers, tools to develop more efficient and effective management of public healthcare providers were implemented.

From 1997 to 2000 had been working as Assistant Medical Director for the area of quality and organization in University Medical Center Ljubljana. Scope of work had been the implementation of the system of internal control and the responsibility for the implementation of the self assessment model of the departments on the basis of the EFQM model.

**Presentation**

Challenges for Future Hospital

Perspective of University Medical Centre Ljubljana

**Mike WARD,  
Editor, Scrip Intelligence, Informa Group**



Mike Ward is editor-in-chief at the Scrip Group focusing on the business challenges facing all stakeholders in the pharma, biotech and medtech industries. He has been covering the life sciences industry for more than 25 years. He has extensive experience in investment banking, consultancy as well as writing about the industry for other leading publications such as Nature, the Economist and BioCentury as well as national newspapers including the Financial Times and International Herald Tribune.

Between 1992 and 2002, Mike was a co-author of many of the European biotech industry reports published by the accountancy houses. In 2010 he was named European Mediscience Commentator of the Year.

**Lilian WIKSTRÖM,  
CEO, Karolinska institutet Holding AB**



Dr Lilian Wikström is the Chief Executive Officer at Karolinska Institutet Innovations AB in Stockholm Sweden.

Before her current appointment, Dr Wikström served as Head of Research and Development at NeuroNova AB. Previously at AstraZeneca she held the responsibility for the Target Discovery activities in the area of pain and central nervous system disorders as well as headed preclinical research projects.

Dr Wikström received a PhD from the Karolinska Institute and has conducted several years of pre- and postdoctoral work at the Whitehead Institute of Biomedical Research in Boston, USA, and at the Karolinska Institute. Her research focus as a Cell and Molecular Biologist has been on studying molecular mechanisms in health and disease, and on understanding the potential of applying regenerative approaches to treating diseases of the central nervous system.

During her career, Dr Wikström has published research and review papers in these topic areas, is the inventor on pending and granted patents, and serves as scientific reviewer both nationally and internationally.

**John WILKINSON,  
Chief Executive, Eucomed**



John Wilkinson has over 25 years experience in the medical devices and diagnostics industry.

He has held senior positions in Becton-Dickinson and Ohmeda, before becoming Chief Executive of a medical imaging start-up venture. This was followed by four years as Director General of the Association of British Healthcare Industries in the United Kingdom.

Having global and regional operational responsibilities in the past has given him an insight into healthcare markets worldwide. In addition, he has lived and worked in the USA.

He has given evidence to the UK Health Select Committee on issues such as the cost benefits of new medical technologies and the speed of, and barriers to, adoption of new innovations within the NHS. He also acted as the joint-secretariat with the UK Department of Health for the Healthcare Industries Task Force (HITF).

John was appointed Chief Executive at Eucomed on 1 April 2008. He was awarded an OBE in the 2010 UK New Year's Honours List for services to the medical technology industry.

**Jean-Jacques ZAMBROWSKI,  
Hospital Physician and Professor of Health Economics,  
Paris Descartes University**



Prof. Jean-Jacques ZAMBROWSKI serves as a senior consulting physician in Internal Medicine and Cardiology at Bichat University Hospital (Paris) and is a member of several scientific societies.

Graduated from Paris University (Master in Health Law and Economics) and the Wharton School - University of Pennsylvania, Philadelphia - USA (PhD in Health Policies & Economics), Professor ZAMBROWSKI gives and supervises teachings in graduate and postgraduate programs and co-manages a Doctoral program on Healthcare Management, Regulatory, Economics and Policies at Paris Descartes University.

Prof. ZAMBROWSKI also teaches at Paris XI University (Master “International development, registration and market access issues of healthcare, health related and “borderline” products and devices”).

A member of ISPOR and of HTAi, Jean-Jacques ZAMBROWSKI is appointed as an expert and a consultant for several public and institutional organizations, both at the national and European level, as well as international.

**Gerd ZETTLMEISSL,  
CEO, Intercell**



©Foto Andi Bruckner, www.andibruckner.com, 00641144102

Gerd Zettlmeissl joined Intercell in 2001 as COO and has served as CEO since 2005.

His scientific background is in Molecular Biology and Protein Biochemistry. He holds a doctorate from the University of Regensburg and joined Behringwerke AG Marburg, Germany in 1985 after conducting five years of academic research at the University of Regensburg and at the Institut Pasteur in Paris. Between 1994 and 1996, Gerd Zettlmeissl was highly involved in the business' merger with Chiron. From the beginning of 2000 onwards, in addition to his global responsibilities, he was CEO of Chiron's German subsidiary, Chiron-Behring. Furthermore, he is the author of numerous scientific publications and inventor/co-inventor of numerous patents in the field of biotechnology.

Gerd Zettlmeissl is a member of the Supervisory Board of the "Helmholtz Zentrum fuer Infektionsforschung GmbH", a public research institute in Braunschweig, Germany.

**Presentation**

"Biotech innovation in the financing environment of pharma, private, public and non-profit organizations - the Intercell experience"

